EKF Diagnostics Holdings plc (EKDHF)

Market Cap	157.01M
Revenue (ttm)	62.84M
Net Income (ttm)	7.81M
Shares Out	n/a
EPS (ttm)	0.02
PE Ratio	20.09
Forward PE	17.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	5,485
Open	0.3176
Previous Close	n/a
Day's Range	0.3176 - 0.3176
52-Week Range	0.2383 - 0.3958
Beta	0.28
RSI	41.12
Earnings Date	Jun 17, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 303
• Stock Exchange: OTCMKTS
• Ticker Symbol: EKDHF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.

Financial numbers in GBP